Clinical Trials with Post-Trial Drug Access

Continue Your Treatment Beyond the Trial

Post-trial drug access is a significant benefit offered by some clinical trials that allows you to continue receiving the study medication after the research phase has concluded. This feature is particularly valuable for patients who respond well to the treatment during the trial.

Why Post-Trial Access Matters for Patients

Many patients worry about what happens after a clinical trial ends, especially if they've been experiencing positive results from the experimental treatment. Post-trial access addresses this concern by providing continued medication supply, often at no cost or reduced cost, while the drug completes its journey through regulatory approval.

What This Means for You

When you participate in a clinical trial with post-trial access provisions, you gain peace of mind knowing that your treatment won't be abruptly discontinued. This is especially important for chronic conditions where treatment continuity is crucial for maintaining health improvements.

The duration and terms of post-trial access vary by study. Some trials offer access until the drug receives market approval, while others may provide it for a fixed period. This benefit can save significant costs and ensure uninterrupted treatment as you transition from being a trial participant to a regular patient.

Key Advantages

Uninterrupted treatment continuity
Potential cost savings on medication
Sustained health benefits from effective treatment
Extended monitoring and medical support
Bridge to market availability

For patients with limited treatment options or those living with chronic conditions, post-trial access can be a deciding factor when choosing which clinical trial to join. It demonstrates the sponsor's commitment to participant welfare beyond the research objectives.

Explore Other Trial Benefits

Discover what other benefits clinical trials can offer to participants

No Placebo

Participants may receive alternative effective medicine instead of a placebo (e.g. sugar pill)

Standard Medicines

Studies with medicines already approved and widely used in standard treatment plans on the European market

Investigational Medicines

Studies testing investigational substances under development that are not yet approved on the EU market

Cost Reimbursement

Costs related to travel, child care or meals may be reimbursed

Partially Remote

Some study visits may be conducted remotely or at home

1-20 of 847 trials

Urothelial Cancer: Disitamab Vedotin with Pembrolizumab

We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.

Bladder CancerEfficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Alpelisib for Megalencephaly-Capillary Malformation Polymicrogyria Syndrome (MCAP)

We are studying whether alpelisib can improve adaptive behavior and overall health in children and adults with MCAP. The trial will also assess the safety and effects of the treatment on brain and spinal cord health.

PIK3CA Related Overgrowth SpectrumMegalencephaly-Capillary Malformation-Polymicrogyria Syndrome>2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational MedicinesInternal MedicineNeurologyPediatrics

Epidermolysis Bullosa: ABCB5+ Stem Cell Treatment

We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.

Epidermolysis Bullosa1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteDermatologyInternal Medicine

Ulcerative Colitis: SAR443122 Study

We are testing different doses of SAR443122 in adults with moderate to severe ulcerative colitis to see how well it works and its safety. The study will also look at improvements in symptoms and quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Standard Medicines Partially RemoteGastroenterologyInternal Medicine

Etripamil Nasal Spray for Pediatric Heart Condition

We are studying whether a nasal spray can help stop episodes of a fast heart rate in children aged 6 to 17. The trial also looks at how safe the spray is for these young patients.

Paroxysmal Supraventricular Tachycardia≤3 monthsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesCardiologyPediatrics

Etrasimod for Adolescents with Ulcerative Colitis

We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyPediatrics

Peripheral T-Cell Lymphoma: Tolinapant with Decitabine/Cedazuridine

We are studying a new treatment combining tolinapant with oral decitabine/cedazuridine for patients with relapsed or refractory peripheral T-cell lymphoma. The goal is to assess safety and effectiveness compared to the current standard treatment.

T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteHematologyOncology

Risankizumab for Moderate to Severe Plaque Psoriasis in Children and Teens

We are studying the long-term safety and effectiveness of risankizumab in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. This follows their participation in a previous study to see how well the treatment works over time.

Plaque Psoriasis>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesAllergologyDermatology

Anemia in Low-Risk Myelodysplastic Syndrome: Luspatercept vs Epoetin Alfa

We are comparing a new treatment, luspatercept, with a standard treatment, epoetin alfa, for patients with low-risk myelodysplastic syndrome who do not need blood transfusions. The goal is to see which treatment better helps manage anemia.

Myelodysplastic Syndrome (MDS)>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyInternal Medicine

Prostate Cancer: Abemaciclib with Abiraterone

We are studying whether adding abemaciclib to standard treatment improves outcomes for men with prostate cancer that has spread and is responsive to hormonal therapy. The trial also evaluates safety and patient quality of life.

High-Risk Metastatic Hormone-Sensitive Prostate CancerConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteOncology

Marstacimab for Severe Hemophilia A and B

We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.

Haemophilia>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematology

Myelodysplastic Syndrome: Oral Azacitidine Study

We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes (MDS)>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visits Post-Trial Drug Access Standard MedicinesHematology